Jennifer Minhon Yeh, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Stomach Neoplasms | 10 | 2024 | 1423 | 2.020 |
Why?
|
Helicobacter Infections | 7 | 2024 | 386 | 1.500 |
Why?
|
Helicobacter pylori | 6 | 2015 | 377 | 1.270 |
Why?
|
Neonatal Screening | 3 | 2023 | 595 | 1.170 |
Why?
|
Cost-Benefit Analysis | 15 | 2022 | 5508 | 0.860 |
Why?
|
Early Detection of Cancer | 8 | 2022 | 3202 | 0.810 |
Why?
|
Li-Fraumeni Syndrome | 1 | 2022 | 117 | 0.750 |
Why?
|
Gastroscopy | 2 | 2015 | 209 | 0.750 |
Why?
|
Life Expectancy | 2 | 2020 | 1248 | 0.640 |
Why?
|
Adenocarcinoma | 6 | 2017 | 6315 | 0.590 |
Why?
|
Mass Screening | 7 | 2022 | 5423 | 0.580 |
Why?
|
Mammography | 4 | 2022 | 2427 | 0.540 |
Why?
|
Pepsinogen A | 1 | 2015 | 13 | 0.510 |
Why?
|
Survivors | 3 | 2016 | 2375 | 0.470 |
Why?
|
Radiography, Thoracic | 1 | 2020 | 1296 | 0.450 |
Why?
|
Neoplasms | 11 | 2021 | 22072 | 0.440 |
Why?
|
Gastrectomy | 1 | 2017 | 679 | 0.400 |
Why?
|
Siblings | 1 | 2016 | 824 | 0.390 |
Why?
|
Markov Chains | 4 | 2010 | 968 | 0.360 |
Why?
|
Models, Theoretical | 3 | 2020 | 3562 | 0.360 |
Why?
|
Stomach Ulcer | 1 | 2010 | 123 | 0.350 |
Why?
|
Quality-Adjusted Life Years | 4 | 2022 | 1724 | 0.330 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2014 | 1259 | 0.310 |
Why?
|
Computer Simulation | 5 | 2022 | 6218 | 0.300 |
Why?
|
Genetic Testing | 4 | 2023 | 3531 | 0.300 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2014 | 1523 | 0.290 |
Why?
|
Breast Neoplasms | 4 | 2022 | 21025 | 0.280 |
Why?
|
Smoking | 3 | 2015 | 9073 | 0.280 |
Why?
|
Echocardiography | 2 | 2020 | 4981 | 0.270 |
Why?
|
Precancerous Conditions | 2 | 2024 | 977 | 0.250 |
Why?
|
Hodgkin Disease | 1 | 2012 | 1378 | 0.240 |
Why?
|
Aftercare | 1 | 2010 | 916 | 0.230 |
Why?
|
Heart Failure | 2 | 2020 | 11847 | 0.210 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2014 | 2128 | 0.210 |
Why?
|
Pelvic Inflammatory Disease | 1 | 2003 | 95 | 0.210 |
Why?
|
Chronic Disease | 1 | 2016 | 9287 | 0.190 |
Why?
|
Models, Economic | 2 | 2013 | 719 | 0.180 |
Why?
|
Young Adult | 8 | 2023 | 58741 | 0.180 |
Why?
|
Endoscopy | 1 | 2010 | 1838 | 0.180 |
Why?
|
Ribonuclease III | 1 | 2021 | 279 | 0.160 |
Why?
|
Adult | 15 | 2023 | 219994 | 0.160 |
Why?
|
China | 3 | 2009 | 2339 | 0.160 |
Why?
|
Quality of Life | 2 | 2020 | 13308 | 0.160 |
Why?
|
Child | 12 | 2023 | 79806 | 0.150 |
Why?
|
Germ Cells | 1 | 2022 | 635 | 0.150 |
Why?
|
Carcinoma | 1 | 2009 | 2331 | 0.150 |
Why?
|
DEAD-box RNA Helicases | 1 | 2021 | 383 | 0.150 |
Why?
|
Humans | 37 | 2024 | 760621 | 0.150 |
Why?
|
Calibration | 3 | 2010 | 816 | 0.150 |
Why?
|
Diabetes Mellitus, Type 1 | 2 | 2022 | 3455 | 0.140 |
Why?
|
Infant, Newborn | 6 | 2023 | 26181 | 0.140 |
Why?
|
Health Priorities | 1 | 2019 | 374 | 0.130 |
Why?
|
Cost of Illness | 2 | 2020 | 1940 | 0.130 |
Why?
|
Islets of Langerhans | 1 | 2022 | 1345 | 0.130 |
Why?
|
Models, Cardiovascular | 1 | 2020 | 978 | 0.120 |
Why?
|
SEER Program | 2 | 2017 | 1530 | 0.120 |
Why?
|
Syndrome | 1 | 2021 | 3280 | 0.120 |
Why?
|
Uterine Neoplasms | 1 | 2023 | 1439 | 0.120 |
Why?
|
Female | 18 | 2023 | 391270 | 0.120 |
Why?
|
Endometrial Neoplasms | 1 | 2023 | 1357 | 0.120 |
Why?
|
Incidence | 5 | 2022 | 21392 | 0.110 |
Why?
|
Survival Rate | 4 | 2019 | 12808 | 0.110 |
Why?
|
Esophageal Neoplasms | 2 | 2017 | 1648 | 0.110 |
Why?
|
Cardiomyopathy, Hypertrophic | 1 | 2023 | 1311 | 0.110 |
Why?
|
Male | 16 | 2021 | 359744 | 0.110 |
Why?
|
Barrett Esophagus | 1 | 2017 | 490 | 0.110 |
Why?
|
Practice Guidelines as Topic | 2 | 2020 | 7475 | 0.110 |
Why?
|
Adolescent | 8 | 2022 | 87810 | 0.110 |
Why?
|
Middle Aged | 10 | 2022 | 220352 | 0.100 |
Why?
|
Sensitivity and Specificity | 3 | 2014 | 14660 | 0.100 |
Why?
|
Hepatitis B Vaccines | 1 | 2013 | 186 | 0.100 |
Why?
|
Mass Vaccination | 1 | 2013 | 109 | 0.100 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2022 | 2919 | 0.100 |
Why?
|
Statistics as Topic | 2 | 2019 | 2362 | 0.090 |
Why?
|
United States | 8 | 2023 | 72461 | 0.090 |
Why?
|
Confidence Intervals | 1 | 2016 | 2932 | 0.090 |
Why?
|
Anthracyclines | 1 | 2012 | 283 | 0.090 |
Why?
|
Immunoglobulins | 1 | 2013 | 859 | 0.080 |
Why?
|
Population | 1 | 2009 | 140 | 0.080 |
Why?
|
Developing Countries | 2 | 2020 | 2868 | 0.080 |
Why?
|
Aged | 7 | 2022 | 169152 | 0.080 |
Why?
|
Models, Statistical | 2 | 2020 | 5075 | 0.080 |
Why?
|
Cohort Studies | 4 | 2014 | 41335 | 0.070 |
Why?
|
Hepatitis B | 1 | 2013 | 701 | 0.070 |
Why?
|
Forecasting | 2 | 2022 | 2932 | 0.070 |
Why?
|
Colombia | 1 | 2008 | 276 | 0.070 |
Why?
|
Health Care Costs | 1 | 2020 | 3258 | 0.070 |
Why?
|
Risk Reduction Behavior | 1 | 2013 | 1109 | 0.070 |
Why?
|
Risk | 2 | 2009 | 9631 | 0.070 |
Why?
|
Infectious Disease Transmission, Vertical | 1 | 2013 | 1348 | 0.060 |
Why?
|
Nutrition Surveys | 1 | 2013 | 1725 | 0.060 |
Why?
|
Secondary Prevention | 1 | 2012 | 1548 | 0.060 |
Why?
|
Multiple Myeloma | 1 | 2023 | 5130 | 0.060 |
Why?
|
Salvage Therapy | 1 | 2012 | 1268 | 0.060 |
Why?
|
Health Services Accessibility | 2 | 2020 | 5397 | 0.060 |
Why?
|
Radiation Injuries | 1 | 2012 | 1183 | 0.060 |
Why?
|
Probability | 1 | 2010 | 2475 | 0.060 |
Why?
|
Ovarian Neoplasms | 1 | 2021 | 4878 | 0.060 |
Why?
|
Neoplasms, Second Primary | 1 | 2012 | 1056 | 0.060 |
Why?
|
Incubators | 1 | 2023 | 5 | 0.060 |
Why?
|
Gastritis, Atrophic | 1 | 2024 | 31 | 0.060 |
Why?
|
Decision Support Techniques | 2 | 2013 | 2001 | 0.060 |
Why?
|
Age Distribution | 1 | 2009 | 2893 | 0.060 |
Why?
|
Immunologic Factors | 1 | 2013 | 1588 | 0.060 |
Why?
|
Aged, 80 and over | 3 | 2020 | 58995 | 0.060 |
Why?
|
Breast | 2 | 2022 | 1963 | 0.050 |
Why?
|
Disease Progression | 3 | 2010 | 13502 | 0.050 |
Why?
|
Metaplasia | 1 | 2024 | 320 | 0.050 |
Why?
|
Infant | 2 | 2022 | 36060 | 0.050 |
Why?
|
Antineoplastic Agents | 2 | 2018 | 13630 | 0.050 |
Why?
|
Neoplasm Staging | 1 | 2017 | 11152 | 0.050 |
Why?
|
Medicare | 2 | 2017 | 6786 | 0.050 |
Why?
|
Pregnancy, Ectopic | 1 | 2003 | 143 | 0.050 |
Why?
|
Primary Health Care | 1 | 2018 | 4647 | 0.050 |
Why?
|
Smoking Cessation | 1 | 2013 | 2064 | 0.050 |
Why?
|
Risk Assessment | 2 | 2013 | 24123 | 0.050 |
Why?
|
Delivery of Health Care | 1 | 2019 | 5325 | 0.050 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2013 | 2125 | 0.050 |
Why?
|
Glutamate Decarboxylase | 1 | 2022 | 239 | 0.050 |
Why?
|
Mortality | 1 | 2012 | 2916 | 0.050 |
Why?
|
Pelvic Pain | 1 | 2003 | 298 | 0.050 |
Why?
|
Combined Modality Therapy | 1 | 2012 | 8552 | 0.040 |
Why?
|
Age Factors | 1 | 2017 | 18416 | 0.040 |
Why?
|
Survival Analysis | 1 | 2012 | 10182 | 0.040 |
Why?
|
Risk Factors | 3 | 2013 | 74359 | 0.040 |
Why?
|
Cause of Death | 1 | 2010 | 3725 | 0.040 |
Why?
|
Case-Control Studies | 1 | 2016 | 22053 | 0.040 |
Why?
|
Tamoxifen | 1 | 2022 | 963 | 0.040 |
Why?
|
Urinary Bladder | 1 | 2023 | 1166 | 0.040 |
Why?
|
Time Factors | 2 | 2013 | 40165 | 0.040 |
Why?
|
Infertility, Female | 1 | 2003 | 759 | 0.040 |
Why?
|
Medical Oncology | 1 | 2009 | 2313 | 0.030 |
Why?
|
Prevalence | 2 | 2024 | 15687 | 0.030 |
Why?
|
Europe | 1 | 2022 | 3441 | 0.030 |
Why?
|
Receptors, Estrogen | 1 | 2022 | 2210 | 0.030 |
Why?
|
Models, Biological | 1 | 2010 | 9467 | 0.030 |
Why?
|
Autoantibodies | 1 | 2022 | 2118 | 0.030 |
Why?
|
Hepatitis B e Antigens | 1 | 2013 | 133 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 1 | 2020 | 36290 | 0.030 |
Why?
|
Hepatitis B Surface Antigens | 1 | 2013 | 301 | 0.020 |
Why?
|
Taiwan | 1 | 2013 | 505 | 0.020 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2010 | 9276 | 0.020 |
Why?
|
Decision Trees | 1 | 2013 | 506 | 0.020 |
Why?
|
Bayes Theorem | 1 | 2019 | 2326 | 0.020 |
Why?
|
Prognosis | 1 | 2010 | 29658 | 0.020 |
Why?
|
Carrier State | 1 | 2013 | 525 | 0.020 |
Why?
|
Follow-Up Studies | 1 | 2010 | 39261 | 0.020 |
Why?
|
Anticarcinogenic Agents | 1 | 2010 | 249 | 0.020 |
Why?
|
Retrospective Studies | 1 | 2017 | 80372 | 0.020 |
Why?
|
Treatment Outcome | 1 | 2014 | 65017 | 0.020 |
Why?
|
Pregnancy | 2 | 2013 | 29749 | 0.020 |
Why?
|
Cardiology | 1 | 2018 | 1723 | 0.020 |
Why?
|
Pilot Projects | 1 | 2018 | 8555 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 11712 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2021 | 17790 | 0.010 |
Why?
|
Aspirin | 1 | 2010 | 3364 | 0.010 |
Why?
|
Mutation | 1 | 2021 | 29932 | 0.010 |
Why?
|
Child, Preschool | 1 | 2019 | 42063 | 0.010 |
Why?
|
Algorithms | 1 | 2010 | 13981 | 0.010 |
Why?
|